MAPT and Alzheimer disease: Escalating evidence has suggested that several miRNAs not only have a great potential as biomarkers in AD diagnosis [13–15], but also are mechanistically associated with AD pathology through distinct mechanisms, such as Aβ level regulation, Tau phosphorylation and synaptic damage, etc [13, 16].